Loading clinical trials...

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Clinical Trials | Clareo Health

RECRUITINGPHASE3

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

NCT07177352•Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Eligibility

Age

50 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

Exclusion Criteria

•Dependency in basic activities of daily living (bADLs) due to cognitive impairment
•Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
•Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
•History of severe, clinically significant central nervous system trauma
•Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

Locations (207)

Banner Alzheimer?s Institute

Phoenix, Arizona, United States

Banner Sun Health Research Institute

Sun City, Arizona, United States

Sun Valley Research Center, Inc.

Imperial, California, United States

Inglewood Clinicals

Inglewood, California, United States

Irvine Center for Clinical Research

Irvine, California, United States

Healthy Brain Clinic

Long Beach, California, United States

Oakland Clinical

Oakland, California, United States

Riverside Clinical

Riverside, California, United States

Syrentis Clinical Research

Santa Ana, California, United States

Cenexel California Neuroscience Research, LLC

Sherman Oaks, California, United States

Key Dates

Start Date

July 2, 2025

Primary Completion Date

July 31, 2035

Completion Date

July 31, 2035

Last Updated

March 9, 2026

Enrollment

13,000

ESTIMATED participants

Conditions

Alzheimers Disease

Interventions

No Intervention

OTHER

Contacts

Reference Study ID Number: WP45722 https://forpatients.roche.com/

CONTACT

888-662-6728 (U.S. and Canada)global-roche-genentech-trials@gene.com

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150

Alzheimers Disease

View study

ACTIVE_NOT_RECRUITINGPHASE2/PHASE3

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005

Alzheimers DiseaseDementia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Inclusion Criteria

Exclusion Criteria

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD Registry)

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD